CNTS + neoDC-Vx

CNTS + neoDC-Vx is an investigational combination immunotherapy composed of two components: - **CNTS** (likely referring to a cancer nanotechnology or cell-based therapy, but no definitive public information is available on this acronym in the context of a drug or biologic). - **neoDC-Vx**, which appears to be a personalized dendritic cell vaccine generated from patient-derived dendritic cells pulsed with tumor-specific neoantigens. Dendritic cell vaccines are designed to stimulate the immune system by presenting tumor antigens and activating T cells against cancer cells. The combination aims to enhance anti-tumor immunity by leveraging both the antigen-presenting capabilities of dendritic cells and potentially additional immunomodulatory effects from CNTS. The precise mechanism depends on the nature of "CNTS," which is not clearly defined in publicly available sources as of June 2025.